Please wait while we load the requested 10-Q report or click the link below:
August 2, 2018
OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights
-Company prioritizes its navicixizumab resources in platinum-resistant ovarian cancer; prepares to share data in Q4 of 2018-
-Cash runway extended by an additional quarter to YE 2019-
REDWOOD CITY, Calif., August 2, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced second quarter 2018 financial results and provided a corporate update. As of June 30, 2018, cash, cash equivalents, and short-term investments totaled $79.9 million.
"The first half of the year has been focused on effective execution in the development of our pipeline of oncology candidates, including navicixizumab, etigilimab (anti-TIGIT) and GITRL-Fc which are being investigated in ongoing clinical trials,” said John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed. “These activities will culminate in important data announcements later this year. We are particularly encouraged by the potential of navicixizumab, our lead product candidate, in the treatment of late-stage ovarian cancer and look forward to sharing single-agent and chemotherapy combination data by the end of the year. We also plan to report first-in-human dose escalation Phase 1a data from our etigilimab program in the fourth quarter of 2018, while early clinical data from our GITRL-Fc program will likely be available in the first half of 2019.”
Navicixizumab (anti-DLL4/VEGF bispecific; OMP-305B83)
The following information was filed by Oncomed Pharmaceuticals Inc (OMED) on Thursday, August 2, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Oncomed Pharmaceuticals Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Oncomed Pharmaceuticals Inc.